Stock Price Quote

AARTI DRUGS LTD.

NSE : AARTIDRUGSBSE : 524348ISIN CODE : INE767A01016Industry : Pharmaceuticals & DrugsHouse : Aarti
BSE414.65-1.25 (-0.3 %)
PREV CLOSE ( ) 415.90
OPEN PRICE ( ) 416.90
BID PRICE (QTY) 414.50 (10)
OFFER PRICE (QTY) 415.25 (20)
VOLUME 6785
TODAY'S LOW / HIGH ( )413.80 419.10
52 WK LOW / HIGH ( )408.2 634.9
NSE414.40-1.85 (-0.44 %)
PREV CLOSE( ) 416.25
OPEN PRICE ( ) 416.50
BID PRICE (QTY) 0.00 (0)
OFFER PRICE (QTY) 0.00 (0)
VOLUME 59840
TODAY'S LOW / HIGH( ) 413.00 419.45
52 WK LOW / HIGH ( )409.05 635
1D 1M 3M 1Y 3Y 5Y
JavaScript chart by amCharts 3.4.2Show all

STOCK SUMMARY

Trade Value ( in Lacs) 28.13
Dividend Yield(%) 0.24
TTM EPS () 13.70
P/E Ratio 30.47
Book Value () 127.02
Face Value () 10
MCap ( in Mn) 38105.23
Price/Earning (TTM) 22.06
Price/Sales (TTM) 1.79
Price/Book (MRQ) 3.29
PAT Margin (%) 6.26
ROCE (%) 13.70
Incorporation Year : 28-09 1984
Management Info
Prakash M Patil - Chairman Rashesh C Gogri - Managing Director
Registered Office

Address Plot No N 198,M I D C,Tarapur Village - Patembhi, Taluka Palghar,
Thane,
Maharashtra-401506

Phone 022-24019025

Email investorrelations@aartidrugs.com

Website www.aartidrugs.com

Registrars Details
MUFG Intime India Pvt Ltd.
C 101, 247 Park,LBS Marg,Vikhroli (West),Mumbai
Listing : BSE, NSE

NEWS

10Jan Aarti Drugs inks pact to acquire 26.25
Aarti Drugs has signed and executed the Share Subscription and Sharehold..
24Dec Aarti Drugs gets EIR from USFDA for Ma
Aarti Drugs has received Establishment Inspection Report (EIR) from Unit..
28Nov Aarti Drugs’ arm incorporates overseas
Aarti Drugs’ subsidiary -- Pinnacle Chile SpA has incorporated an overse..
28Nov Aarti Drugs rises as its arm incorpora
Aarti Drugs is currently trading at Rs. 463.00, up by 6.50 points or 1.4..
04Oct Aarti Drugs gets GMP certificate from
Aarti Drugs has received ‘Certificate of GMP Compliance of a Manufacture..

Financials

JavaScript chart by amCharts 3.4.2Show all
JavaScript chart by amCharts 3.4.2Income Growth (RHS %)
in Millions
QTR Sep 24 ANNUAL 24
Net Profit303.9000000000011418.8
Gross Profit 408.900000000001 1924.8
Operating Profit 599.2000000000012703.1
Net Sales 5430.922669.1

ROLLING FORWARD P/E (EOD)

JavaScript chart by amCharts 3.4.2Show all
JavaScript chart by amCharts 3.4.212 Months Rolling Forward P/E (X)

EVENT CALENDAR

Record DateBonus Ratio
30-Sep-203 : 1
24-Mar-151 : 1

peer group

Wockhardt (BSE)
peergroup  1428.00 (10.00%)
M.Cap ( in Cr)21120.59
Astrazeneca Pharma I (BSE)
peergroup  7077.40 (1.58%)
M.Cap ( in Cr)17402.13
Mankind Pharma (BSE)
peergroup  2620.00 (4.17%)
M.Cap ( in Cr)107005.41
Torrent Pharma (BSE)
peergroup  3265.55 (3.12%)
M.Cap ( in Cr)108925.28
RPG Life Sciences (BSE)
peergroup  2171.65 (4.72%)
M.Cap ( in Cr)3540.59

Shareholding Pattern

MUTUAL FUNDS/UTI 7.78%
PROMOTERS 55.38%
NON-INSTITUTION 33.57%
FI/BANKS/INSURANCE 0.08%
GOVERNMENT 0%
FII 0%

About Aarti Drugs Ltd.

Aarti Drugs Ltd. was incorporated in the year 1984. Its today's share price is 414.65. Its current market capitalisation stands at Rs 3810.52 Cr. In the latest quarter, company has reported Gross Sales of Rs. 22669.11 Cr and Total Income of Rs.22710.94 Cr. The company's management includes Rushikesh Deole, Ajit Eledath Venugopalan, Sandeep M Joshi, Hasmukh Dedhia, Neha R Gada, Bhaskar Narayan Thorat, Ankit Paleja, Narendra J Salvi, Uday M Patil, Harit P Shah, Harshit M Savla, Rashesh C Gogri, Prakash M Patil, Prakash M Patil, Chandrakant V Gogri.

It is listed on the BSE with a BSE Code of 524348 , NSE with an NSE Symbol of AARTIDRUGS and ISIN of INE767A01016. It's Registered office is at Plot No N 198,M I D C,Tarapur Village - Patembhi, Taluka PalgharThane-401506, Maharashtra. Their Registrars are K FIN Technologies Ltd.-(Karvy Fintech Pvt Ltd.) It's auditors are GBCA & Associates, Gokhale & Sathe, Kirtane & Pandit LLP, Parikh Joshi & Kothare

1.NSE exchange is Stopping the facility of Stop-Loss Market (SL-M) orders In option trade from 27th Sept 2021 to avoid freak trades and reduce its impact significantly. 2. Introduction of T+1 rolling settlement on optional basis. Stock Exchange may choose to offer T+1 settlement cycle. There shall be no netting between T+1 and T+2 settlements. Circular provisions come into force with effect from Jan: @SEBI_India 3. Stock Brokers can accept securities as margin from clients only by way of pledge in the depository system w.e.f. September 01, 2020. 4. Update your email id and mobile number with your stock broker / depository participant and receive OTP directly from depository on your email id and/or mobile number to create pledge. 5. Check your securities / MF / bonds in the consolidated account statement issued by NSDL/CDSL every month. 6.Do not share sensitive information like User ID, Password, OTP, etc., with anyone. Regards, Nirmal Bang.
1.NSE exchange is Stopping the facility of Stop-Loss Market (SL-M) orders In option trade from 27th Sept 2021 to avoid freak trades and reduce its impact significantly. 2. Introduction of T+1 rolling settlement on optional basis. Stock Exchange may choose to offer T+1 settlement cycle. There shall be no netting between T+1 and T+2 settlements. Circular provisions come into force with effect from Jan: @SEBI_India 3. Stock Brokers can accept securities as margin from clients only by way of pledge in the depository system w.e.f. September 01, 2020. 4. Update your email id and mobile number with your stock broker / depository participant and receive OTP directly from depository on your email id and/or mobile number to create pledge. 5. Check your securities / MF / bonds in the consolidated account statement issued by NSDL/CDSL every month. 6.Do not share sensitive information like User ID, Password, OTP, etc., with anyone. Regards, Nirmal Bang.

© NIRMAL BANG. All rights reserved

Designed , Developed & Content Powered by Accord Fintech Pvt. Ltd.

Open an Account
FOR AFREE *DEMAT & BROKING ACCOUNT

Please fill in the details below

Close X

(Note - You will receive a call from our sales executive)

CLOSE X

RISK DISCLOSURES ON DERIVATIVES

  • 9 out of 10 individual traders in equity Futures and Options Segment, incurred net losses.
  • On an average, loss makers registered net trading loss close to ₹ 50,000.
  • Over and above the net trading losses incurred, loss makers expended an additional 28% of net trading losses as transaction costs.
  • Those making net trading profits, incurred between 15% to 50% of such profits as transaction cost.

Source:

1. SEBI study dated January 25, 2023 on “Analysis of Profit and Loss of Individual Traders dealing in equity Futures and Options (F&O) Segment”, wherein Aggregate Level findings are based on annual Profit/Loss incurred by individual traders in equity F&O during FY 2021-22.
Close X
OPEN

DEMAT ACCOUNT

AND START YOUR

INVESTMENT

JOURNEY WITH US
(You will receive a Call & SMS from our end)
Popup-Character

Disclaimer: NIRMAL BANG SECURITIES PVT LTD: Investment in Securities market are subject to market risks. Read all the related documents carefully before investing. Please read the Do’s and Don’ts prescribed by the Commodity Exchange before trading. We do not offer PMS Service for the Commodity segment. Opening of account will not guarantee allotment of shares in IPO. Investors are requested to do their own due diligence before investing in any IPO. The securities quoted are exemplary and are not recommendatory. BSE (Member ID- 498): INB011072759, INF011072759, Exchange Registered Member in CDS; NSE MEMEBR ID- 09391): INB230939139, INF230939139, INE230939139; MSEI Member ID-1067): INB260939138, INF260939138, INE260939139: Single Registration No. INZ000202536, PMS Registration No: INP000002981; Research Analyst Registration No: INH000001766; NSDL/ CDSL: IN-DP-CDSL 37-99; Exchange Member ID: MCX - 56460, NCDEX - 1268, ICEX – 2073. Regd. Office: B-2, 301/302, 3rd Floor, Marathon Innova, Off Ganpatrao Kadam Marg, Lower Parel (W), Mumbai - 400013. Tel: 62738000/01; Fax: 62738010 | *NIRMAL BANG NIVESHALAYA PVT LTD: ARN – 111233, Mutual Fund Distributor. Mutual Fund Investments are subject to market risks. Please read the offer documents carefully before Investing.” Regd. Office: B - 201, Khandelwal House, Poddar Road, Near Poddar Park, Malad (East). Mumbai – 400097. | **NIRMAL BANG INSURANCE BROKING PVT LTD: IRDAI Registration No: 795 and Registration Code For the Insurance Broker: IRDAI/DB889/2021. Insurance is the subject matter of the solicitation. For more details on policy terms, conditions, exclusions, limitations, please refer/read policy brochure carefully before concluding sale.